Nissay Asset Management Corp Amgen Inc Transaction History

Nissay Asset Management Corp

$15.5 Billion
Q3 2024

A detailed history of Nissay Asset Management Corp transactions in Amgen Inc stock. As of the latest transaction made, Nissay Asset Management Corp holds 115,229 shares of AMGN stock, worth $30.5 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

115,229

Previous 106,655 8.04%

Holding current value

$30.5 Million

Previous $33.3 Million 11.41%

% of portfolio

0.24%

Previous 0.22%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$309.38 - $337.38 $2.65 Million - $2.89 Million	8,574 Added 8.04%	115,229 $37.1 Million
Q2 2024 Aug 14, 2024	BUY	$262.75 - $319.31 $3 Million - $3.65 Million	11,423 Added 11.99%	106,655 $33.3 Million
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $5.63 Million - $6.8 Million	20,950 Added 28.2%	95,232 $27.1 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $1.75 Million - $1.97 Million	6,828 Added 10.12%	74,282 $21.4 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $990,265 - $1.23 Million	4,529 Added 7.2%	67,454 $18.1 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $167,987 - $198,642	-784 Reduced 1.23%	62,925 $14 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $515,704 - $628,556	-2,284 Reduced 3.46%	63,709 $15.4 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $395,534 - $502,574	1,727 Added 2.69%	65,993 $17.3 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $51,401 - $57,971	229 Added 0.36%	64,266 $14.5 Million
Q2 2022 Aug 15, 2022	SELL	$230.71 - $256.74 $30,684 - $34,146	-133 Reduced 0.21%	64,037 $15.6 Million
Q1 2022 May 16, 2022	BUY	$219.27 - $242.57 $150,638 - $166,645	687 Added 1.08%	64,170 $15.5 Million
Q4 2021 Feb 14, 2022	BUY	$198.88 - $227.6 $257,549 - $294,742	1,295 Added 2.08%	63,483 $14.3 Million
Q3 2021 Nov 10, 2021	SELL	$212.27 - $248.7 $60,709 - $71,128	-286 Reduced 0.46%	62,188 $13.2 Million
Q2 2021 Aug 13, 2021	SELL	$233.58 - $259.14 $679,017 - $753,319	-2,907 Reduced 4.45%	62,474 $15.2 Million
Q1 2021 May 11, 2021	SELL	$221.91 - $258.6 $463,569 - $540,215	-2,089 Reduced 3.1%	65,381 $16.3 Million
Q4 2020 Feb 08, 2021	SELL	$216.38 - $257.67 $927,188 - $1.1 Million	-4,285 Reduced 5.97%	67,470 $15.5 Million
Q3 2020 Oct 20, 2020	SELL	$234.65 - $260.95 $2.18 Million - $2.42 Million	-9,271 Reduced 11.44%	71,755 $18.2 Million
Q2 2020 Jul 27, 2020	BUY	$197.81 - $242.74 $994,588 - $1.22 Million	5,028 Added 6.62%	81,026 $19.1 Million
Q1 2020 May 05, 2020	BUY	$182.24 - $241.7 $173,674 - $230,340	953 Added 1.27%	75,998 $15.4 Million
Q4 2019 Feb 14, 2020	SELL	$189.21 - $243.2 $945,671 - $1.22 Million	-4,998 Reduced 6.24%	75,045 $18.1 Million
Q3 2019 Nov 14, 2019	BUY	$174.11 - $208.62 $268,129 - $321,274	1,540 Added 1.96%	80,043 $15.5 Million
Q2 2019 Aug 07, 2019	SELL	$166.7 - $195.41 $968,193 - $1.13 Million	-5,808 Reduced 6.89%	78,503 $14.5 Million
Q1 2019 May 03, 2019	SELL	$180.87 - $203.88 $844,843 - $952,323	-4,671 Reduced 5.25%	84,311 $16 Million
Q4 2018 Feb 06, 2019	BUY	$178.4 - $208.25 $1.56 Million - $1.82 Million	8,759 Added 10.92%	88,982 $17.3 Million
Q3 2018 Oct 30, 2018	BUY	$185.29 - $208.89 $1.35 Million - $1.52 Million	7,266 Added 9.96%	80,223 $16.6 Million
Q2 2018 Aug 08, 2018	SELL	$166.05 - $186.51 $412,302 - $463,104	-2,483 Reduced 3.29%	72,957 $13.5 Million
Q1 2018 May 14, 2018	SELL	$169.43 - $198.0 $588,599 - $687,852	-3,474 Reduced 4.4%	75,440 $12.9 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $13.3 Million - $14.9 Million	78,914	78,914 $13.7 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.

Account

Nissay Asset Management Corp Amgen Inc Transaction History